๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations

โœ Scribed by Kenneth E. Sherman; Russell Fleischer; Katherine Laessig; Jeffrey Murray; William Tauber; Debra Birnkrant


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
109 KB
Volume
46
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Variants in interferon-alpha pathway gen
โœ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 270 KB ๐Ÿ‘ 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-โฃ) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may